Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 38

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 38
---
 of Notre Dame and a B.A. in Economics from Boston College.

Craig Malzahn, age 52, was appointed as EVP, Product Development and Chief Technology Officer in March 2025 and has been with the Company since November 2019. Prior to joining us, Mr. Malzahn was the Vice President and Site Head for GlaxoSmithKline plc (“GSK”), a pharmaceutical company, from January 2017 to October 2019. Mr. Malzahn was the Director, BioPharmaceutical Technology at GSK from April 2016 to December 2016 and the Director, Supply Chain at GSK from December 2012 to March 2016. Prior to GSK, Mr. Malzahn was Senior Director, Supply Chain at Human Genome Sciences (“HGS”) and held various roles at HGS from November 2003 to November 2012. Preceding HGS, Mr. Malzahn held various manufacturing positions at Baxter and North American Vaccines. Mr. Malzahn received an M.S. in Biotechnology from Johns Hopkins University and a B.S. in Biology from Virginia Tech.

<div align='center'>24</div>

EXECU TIVE COMPENSATION Compensation Discussion and Analysis This Compensation Discussion and Analysis (“CD&A”) explains our compensation philosophy, policies and decisions for 2024 for the following executives, whom we refer to in this CD&A and in the related tables as our named executive officers (“NEOs”): • Curran Simpson, who was appointed as our President and Chief Executive Officer effective July 1, 2024; • Mitchell Chan, who was appointed as our EVP, Chief Financial Officer effective September 16, 2024; • Stephen Pakola, M.D., our EVP, Chief Medical Officer; • Patrick J. Christmas, our EVP, Chief Strategy and Legal Officer; • Olivier Danos, Ph.D., our EVP, Chief Scientific Officer; • Kenneth T. Mills, our former President and Chief Executive Officer; and • Vit Vasista, our former EVP, Chief Financial Officer. Executive Summary of Our 2024 Achievements We are a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemids